Fosamax - drug for treatment of Paget disease, osteoporosis at women in a postmenopause, osteoporosis at men, a hypercalcemia at malignant tumors. Active alendronate ingredient - non-hormonal specific inhibitor of an osteoclastic bone resorption, suppresses osteoclasts. Taking of Fosamax stimulates bone formation, recovers positive balance between a resorption and recovery of a bone, progressively increases the mineral density of bones, promotes formation of a normal bone tissue with normal histologic structure.

A tricyclic antidepressant with a relatively short latency period. It has almost no sedative effect. therapeutical indications include: depressive phases of a manic-depressive psychosis, all other forms of endogenous depression (reactive and neurotic). In combination with amitriptyline it is used for depressions that occurred during treatment with reserpine. In combination with neuroleptics, it is used in the treatment of depression that developed during treatment of schizophrenic psychoses.